Key result
In vitro sensitivity of collagen-induced platelet aggregation to aspirin was not enhanced in patients with von Willebrand's disease compared to normal subjects, despite prolonged in vivo bleeding times.
Why the study?
Does von Willebrand's disease increase the in vitro sensitivity of platelets to aspirin compared to normal subjects?
Case-Control (n=25)
Does von Willebrand's disease increase the in vitro sensitivity of platelets to aspirin compared to normal subjects?
In patients with von Willebrand's disease, abnormal in vivo bleeding time prolongation with aspirin is not explained by enhanced in vitro platelet sensitivity to aspirin.
Answers are grounded in this paper and cite their sources.
In vitro aspirin sensitivity is not enhanced in von Willebrand's disease; leaves open alternative mechanisms for prolonged bleeding times.
The sensitivity of collagen-induced platelet aggregation to aspirin was measured in vitro on platelet-rich plasma from 20 normal subjects and five patients with von Willebrand's disease. Although aspirin tolerance tests performed in vivo at the same time showed an abnormal prolongation of the bleeding time in three of the patients studied, no evidence was found for an enhanced sensitivity to aspirin in vitro.
No takes yet. Share an insight, caveat, or question.
Leslie et al. (1970) conducted a case-control in von Willebrand's disease (n=25). Aspirin vs. Normal subjects was evaluated on Sensitivity of collagen-induced platelet aggregation to aspirin in vitro. In vitro sensitivity of collagen-induced platelet aggregation to aspirin was not enhanced in patients with von Willebrand's disease compared to normal subjects, despite prolonged in vivo bleeding times.
Synapse has enriched 10 related papers. Consider them for comparative context: